<!DOCTYPE HTML>
<!--
	Phantom by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
	<head>
		<title>DC Johnson - Neurtral Evolution</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="assets/css/main.css" />
		<noscript><link rel="stylesheet" href="assets/css/noscript.css" /></noscript>
	</head>
	<body class="is-preload">
		<!-- Wrapper -->
			<div id="wrapper">

				<!-- Header -->
					<header id="header">
						<div class="inner">

							<!-- Logo -->
								<a href="index.html" class="logo">
									<span class="symbol"><img src="images/logo.svg" alt="" /></span><span class="title">DC Johnson - Portfolio</span>
								</a>

							<!-- Nav -->
								<nav>
									<ul>
										<li><a href="#menu">Menu</a></li>
									</ul>
								</nav>

						</div>
					</header>

				<!-- Menu -->
					<nav id="menu">
						<h2>Menu</h2>
						<ul>
							<li><a href="index.html">Home</a></li>
							<li><a href="mangement.html">Managerial Experience</a></li>
							<li><a href="data.p1.html">Data management</a></li>
							<li><a href="publications.html">Publications</a></li>
							<li><a href="elements.html">C.Vs</a></li>
						</ul>
					</nav>

				<!-- Main -->
					<div id="main">
						<div class="inner">
							<h1>Neutral Evolution</h1>
							<p><b>Background</b><br>
							An ICR colleague resurrected the <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26780609">evolutionary theory of neutrality</a> and measured the concept through bulk 
							sequencing data. Sottoria had showed that some tumours are driven by such strong initial drivers, that they evolve neutrally and are more resistent to forming sub-clones 
							in response to selectional pressure from the environment. Sottoriva suggested that tumour neutrality could have prognostic importance, we were able to be the first to 
							investigate this. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28827410"></a> The approach by 
							<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26780609"> Sottoriva et al </a> has been <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30374075"> critiqued 
							</a> in the literature. The practical problem is influence of somatic copy number changes and the stringency of the R<sup>2</sup> cut-off. It is likely that R<sup>2</sup> 
							needs to be assessed for each tumour type, rather than a definitive threshold for all tumours. The usefulness of this method for clinical predication is questionable, as 
							tumour neutrality is measured during a particular time span and changing the environment could change a tumour neutral tendency. So that neutral evolution status is a moving target, 
							and clinicians would be better served taking serial biopsies in order direct therapeutic approaches.  R<sup>2</sup> measure could be used as a means to assess how directly 
							a drug targets a tumour type, i.e. whether a drug affects a tumour directly or via the micro environment. <br><br>
							Below is a pictorial representation of examining neutral evolution with bulk sequencing. 

							</p>
							<span class="image main"><img src="images/neu.fig1.png" alt="" /></span>
							<p><b>Distribution</b><br>
							In order to undertake this analysis we used a standard sequencing pipeline for whole exomes. To assess R<sup>2</sup> we calculated the gradient of the distribution of VAF for 
							cumulative mutations over time. Mutations where considered were there were more than 10 reads, with at least 3 mutations. And we only considered samples that had 12 private 
							mutations between a frequency of 0.12 and 2.4. We corrected for copy number at each mutation as adjusted and generated a R<sup>2</sup> score. <br><br>
							It can be seen in the figure beneath, when considering the distribution of sub-clonal mutations below 0.6, the relationship between the number of mutations and average variant 
							allele frequency (VAF) is linear in neutral samples indicating absence of subclonity.
							</p>
							<span class="image main"><img src="images/neu.fig2.png" alt="" /></span>
							<p><b>Subgroups and mutational signatures</b><br>
							As expected, neutral tumour signature was seen to be enriched in myeloma subgroups (figure left), where disease transition has been shown to more rapid from the precursor MGUS disease. 
							The numbers were small but I was able to show that micro-environment enriched mutations were more prevalent in the non-neutral samples, indicating that these samples were 
							likely to be more micro-environment sensitive (figure right).
							</p>
							<span class="image main"><img src="images/neu.fig3.png" alt="" /></span>
							<p><b>Survival and response</b><br>
							Indeed, when we compared OS and PFS in auto treated patients where the bulk of the tumour is removed we see little difference. Whilst in non-intensively treated patient 
							received IMIDs, where the response to therapy is micro-environment dependent, we do see a difference in outcome. Assessing independent data-sets from MMRF Commpass 
							cancer-register, we see a similar pattern.</p>
							<span class="image main"><img src="images/neu.fig4.png" alt="" /></span>
							<p><b>Programs and packages</b><br>
							Survival analysis - survival, survivalminer, glmnet; Sequencing analysis - SnpEff, Onctotator, MutsigCV, GenVisR; Mutational signatures - deconstructSigs; 
							Data-visualisation - ggplot2, vioplot, matplotlib, seaborn.</p>
							<p><b>References</b><br>
							◦ Neutral tumor evolution in myeloma is associated with poor prognosis. Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF. Blood. 2017 Oct 5;130(14):1639-1643. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28827410"> PMID: 28827410. </a> <br><br>
							◦ Identification of neutral tumor evolution across cancer types. Williams MJ, Werner B, Barnes CP, Graham TA, Sottoriva A. Nature Genetics 2016, Mar;48(3):238-244. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26780609"> PMID: 26780609. </a> <br><br>
							◦ Neutral tumor evolution? Tarabichi M, Martincorena I, Gerstung M, Leroi AM, Markowetz F et al. Nature Genetics 2018, Dec;50(12):1630-1633. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30374075"> PMID: 30374075. </a> <br><br>
							◦ Reply to 'Neutral tumor evolution?' Heide T, Zapata L, Williams MJ, Werner B, Caravagna G, Barnes CP. Nature Genetics 2018, Dec;50(12):1633-1637. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30374073"> PMID: 30374073. </a> <br><br></p><p>
					</div>

				<!-- Footer -->
					<footer id="footer">
						<div class="inner">
							<section>
								<h2>Get in touch</h2>
								<form method="post" action="#">
									<div class="fields">
										<div class="field half">
											<input type="text" name="name" id="name" placeholder="Name" />
										</div>
										<div class="field half">
											<input type="email" name="email" id="email" placeholder="Email" />
										</div>
										<div class="field">
											<textarea name="message" id="message" placeholder="Message"></textarea>
										</div>
									</div>
									<ul class="actions">
										<li><input type="submit" value="Send" class="primary" /></li>
									</ul>
								</form>
							</section>
							<section>
								<h2>Follow</h2>
								<ul class="icons">
										<li><a href="@davecj23" class="icon brands style2 fa-twitter"><span class="label">Twitter</span></a></li>
										<li><a href="https://github.com/dcjohnson23" class="icon brands style2 fa-github"><span class="label">GitHub</span></a></li>
										<li><a href="https://scholar.google.co.uk/citations?user=yidb_JkAAAAJ&hl=en" class="icon brands style2 fa-google"><span class="label">Google</span></a></li>
										<li><a href="https://linkedin.com/in/david-johnson-ab90033b/" class="icon brands style2 fa-linkedin"><span class="label">Linkedin</span></a></li>
										<li><a href="davcj23@gmail.com" class="icon solid style2 fa-envelope"><span class="label">Email</span></a></li>
								</ul>
							</section>
							<ul class="copyright">
								<li>&copy; Untitled. All rights reserved</li><li>Design: <a href="http://html5up.net">HTML5 UP</a></li>
							</ul>
						</div>
					</footer>

			</div>

		<!-- Scripts -->
			<script src="assets/js/jquery.min.js"></script>
			<script src="assets/js/browser.min.js"></script>
			<script src="assets/js/breakpoints.min.js"></script>
			<script src="assets/js/util.js"></script>
			<script src="assets/js/main.js"></script>

			<div>Icons made by <a href="https://www.flaticon.com/authors/eucalyp" title="Eucalyp">Eucalyp</a> from <a href="https://www.flaticon.com/"             title="Flaticon">www.flaticon.com</a> is licensed by <a href="http://creativecommons.org/licenses/by/3.0/"             title="Creative Commons BY 3.0" target="_blank">CC 3.0 BY</a></div>
	</body>
</html>